Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016

  • ID: 3802725
  • Report
  • 136 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Astellas Pharma Inc.
  • Batu Biologics, Inc.
  • Boehringer Ingelheim GmbH
  • Eddingpharm
  • Eli Lilly and Company
  • MORE
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016

Summary

‘Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016’, provides in depth analysis on Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Astellas Pharma Inc.
  • Batu Biologics, Inc.
  • Boehringer Ingelheim GmbH
  • Eddingpharm
  • Eli Lilly and Company
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) Overview

Therapeutics Development

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Stage of Development

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Therapy Area

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Indication

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Companies

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Universities/Institutes

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Advenchen Laboratories, LLC

Amgen Inc.

ArQule, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Batu Biologics, Inc.

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celon Pharma Sp. z o.o.

Daiichi Sankyo Company, Limited

Debiopharm International SA

Eddingpharm

Eisai Co., Ltd.

Eli Lilly and Company

Hutchison MediPharma Limited

Incyte Corporation

Johnson & Johnson

Kaken Pharmaceutical Co., Ltd.

Les Laboratoires Servier SAS

Nobelpharma Co., Ltd.

Novartis AG

Principia Biopharma Inc.

Vichem Chemie Research Ltd.

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Drug Profiles

ARQ-087 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-5878 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-4547 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1163877 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1179470 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1187982 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986036 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPL-043 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Debio-1347 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-1123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-7090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDP-317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erdafitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GP-369 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMPL-453 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-54828 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infigratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-27 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenvatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lucitanib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2874455 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nintedanib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palifermin (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRN-1371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPT-835 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-49076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trafermin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trafermin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vallovax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Dormant Projects

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Discontinued Products

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Featured News & Press Releases

Jun 06, 2016: Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology Annual Meeting

May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology

May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma

May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis

May 09, 2016: LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma

Apr 20, 2016: Eisai Announces Non-Clinical Research Findings At Aacr 107Th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus

Apr 15, 2016: Debiopharm International announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor

Apr 12, 2016: Highly Anticipated New Treatment Option Now Available for Canadians with Select Type of Thyroid Cancer

Mar 09, 2016: Lenvima (lenvatinib) Now Available in Israel as Important New Treatment for People with Advanced Thyroid Cancer

Mar 03, 2016: Batu Biologics Recruits Diagnostics Expert to Oversee Precision-Medicine Company Arm

Feb 25, 2016: Eisai Slams the New Cancer Drug Fund that Further Delays Patient Access to New Cancer Drug

Feb 25, 2016: New analysis confirms OFEV (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

Jan 27, 2016: NICE recommends nintedanib for idiopathic pulmonary fibrosis

Jan 26, 2016: Boehringer Ingelheim is Pleased to Welcome Green Light from the National Institute for Health and Care Excellence (NICE) for Its Medicine for Rare Lung Disease

Jan 18, 2016: U.S. FDA Accepts For Priority Review sNDA For Eisai’S Anticancer Agent Lenvatinib Seeking Approval For Renal Cell Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 136List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Advenchen Laboratories, LLC, H1 2016

Pipeline by Amgen Inc., H1 2016

Pipeline by ArQule, Inc., H1 2016

Pipeline by Astellas Pharma Inc., H1 2016

Pipeline by AstraZeneca Plc, H1 2016

Pipeline by AVEO Pharmaceuticals, Inc., H1 2016

Pipeline by Batu Biologics, Inc., H1 2016

Pipeline by Bayer AG, H1 2016

Pipeline by Boehringer Ingelheim GmbH, H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by Celon Pharma Sp. z o.o., H1 2016

Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Pipeline by Debiopharm International SA, H1 2016

Pipeline by Eddingpharm, H1 2016

Pipeline by Eisai Co., Ltd., H1 2016

Pipeline by Eli Lilly and Company, H1 2016

Pipeline by Hutchison MediPharma Limited, H1 2016

Pipeline by Incyte Corporation, H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016

Pipeline by Les Laboratoires Servier SAS, H1 2016

Pipeline by Nobelpharma Co., Ltd., H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Principia Biopharma Inc., H1 2016

Pipeline by Vichem Chemie Research Ltd., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016

Discontinued Products (Contd..1), H1 2016

Discontinued Products (Contd..2), H1 2016 121List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Astellas Pharma Inc.
  • Batu Biologics, Inc.
  • Boehringer Ingelheim GmbH
  • Eddingpharm
  • Eli Lilly and Company
  • MORE
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) pipeline Target constitutes close to 31 molecules. Out of which approximately 29 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Fibroblast Growth Factor Receptor 2 - Pipeline Review, H1 2016, outlays comprehensive information on the Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) Fibroblast growth factor receptor 2 (FGFR2) or CD332 is a protein encoded by the FGFR2 gene. Ligand binding leads to the activation of several signaling cascades. It plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, embryonic development, osteoblast differentiation, proliferation, apoptosis, normal skeleton development, lung morphogenesis, osteogenesis and skin development. It promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 8, 8, 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Furthermore, this report also reviews key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Advenchen Laboratories, LLC
Amgen Inc.
ArQule, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Batu Biologics, Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celon Pharma Sp. z o.o.
Daiichi Sankyo Company, Limited
Debiopharm International SA
Eddingpharm
Eisai Co., Ltd.
Eli Lilly and Company
Hutchison MediPharma Limited
Incyte Corporation
Johnson & Johnson
Kaken Pharmaceutical Co., Ltd.
Les Laboratoires Servier SAS
Nobelpharma Co., Ltd.
Novartis AG
Principia Biopharma Inc.
Vichem Chemie Research Ltd.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll